![Michael Saylor Issues Crucial Bitcoin Message as Market Uncertainty Persists](https://i-invdn-com.investing.com/news/LYNXMPEE0802O_S.jpg)
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.14 | 0.15 | 0.01 |
Stocks | 97.87 | 97.87 | 0.00 |
Bonds | 0.23 | 0.23 | 0.00 |
Other | 1.76 | 1.76 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 23.78 | 19.16 |
Price to Book | 4.10 | 4.43 |
Price to Sales | 1.77 | 2.56 |
Price to Cash Flow | 19.55 | 17.05 |
Dividend Yield | 0.59 | 1.09 |
5 Years Earnings Growth | 11.16 | 13.14 |
Number of long holdings: 115
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
UnitedHealth | US91324P1021 | 11.20 | 523.51 | -1.44% | |
Boston Scientific | US1011371077 | 10.68 | 106.11 | -0.03% | |
Eli Lilly | US5324571083 | 5.93 | 844.27 | -3.16% | |
Danaher | US2358511028 | 5.56 | 206.30 | +1.33% | |
Penumbra Inc | US70975L1070 | 4.66 | 268.67 | -1.55% | |
Insulet | US45784P1012 | 3.43 | 280.56 | -0.55% | |
Masimo | US5747951003 | 3.24 | 181.31 | +0.96% | |
Stryker | US8636671013 | 3.19 | 385.18 | -0.82% | |
argenx ADR | US04016X1019 | 2.72 | 639.41 | -1.83% | |
Thermo Fisher Scientific | US8835561023 | 2.15 | 531.85 | -0.15% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fidelity 500 Index Institutional Pr | 638.76B | 2.78 | 11.89 | 13.75 | ||
Fidelity Contrafund K | 128.94B | 5.45 | 16.08 | 16.15 | ||
Fidelity Contrafund | 128.94B | 5.42 | 16.00 | 16.05 | ||
Fidelity Total Market Index Instl b | 108.28B | 3.06 | 11.30 | 13.16 | ||
Fidelity Blue Chip Growth | 68.75B | 2.25 | 15.58 | 18.45 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review